Press release 📈 Stocks 🌍 Israel

Nasus Pharma Appoints Nir Sassi as CFO to Lead Financial Operations

Nasus Pharma names industry veteran Nir Sassi as CFO, bolstering its leadership team ahead of the planned NS002 Phase 3 clinical trial and a projected topline data readout in the first quarter of 2027.

🕐 1 min read

1 assets impacted. Net bias: 0 Bullish, 0 Bearish, 1 Neutral. Strongest signal: NSRX → 2/10 (60% confidence).

📊 Affected Assets (1)

NSRX
Neutral 🤖 60%
📅 Short-term 🌍 US · Explicit

The appointment of Nir Sassi as CFO, effective November 11, 2026, adds financial leadership with nearly 25 years of experience ahead of the planned NS002 Phase 3 study initiation in Q4 2026 and topline readout in Q1 2027. However, the release contains no hard financial figures, guidance change or clinical result, so it does not materially alter the investment case. The pipeline milestones cited are already stated plans, not new data.

Catalysts
  • • NS002 pivotal Phase 3 study planned to start in Q4 2026
  • • Topline data readout expected Q1 2027
Risk Factors
  • • Phase 3 timing and outcomes remain uncertain
  • • Company may need additional financing, as noted in the forward-looking statements

🎯 Key Takeaways

  • Nir Sassi assumed the role of Chief Financial Officer at Nasus Pharma on November 11, 2026.
  • The company plans to initiate a pivotal Phase 3 study for its lead candidate, NS002, in the fourth quarter of 2026.
  • Topline data from the NS002 Phase 3 study is expected to be released in the first quarter of 2027.
  • Sassi previously served as CFO at two Nasdaq-listed biopharmaceutical companies, including Indaptus Therapeutics.

📝 Executive Summary

Nasus Pharma Ltd. has appointed Nir Sassi as its new Chief Financial Officer, effective November 11, 2026. Sassi brings nearly 25 years of experience in capital markets and biopharmaceutical finance to the company as it prepares for a pivotal Phase 3 study of its lead candidate, NS002, in the fourth quarter of 2026.

❓ FAQ

Does the new CFO change Nasus Pharma's outlook?

Not directly. He brings nearly 25 years of finance and capital markets experience, including CFO roles at two Nasdaq-listed biotech companies, but the announcement contains no financial figures or new guidance.

What are the next key dates for NSRX investors?

The company plans to start its NS002 pivotal Phase 3 study in the fourth quarter of 2026 and report topline data in the first quarter of 2027.